CDCA3 (Cell Division Cycle Associated 3)

News alerts, weekly reports and conference planners

Entrez ID:

CDCA3 overexpression	Non Small Cell Lung Cancer	CDCA3 overexpression	Non Small Cell Lung Cancer	carboplatin Sensitive: C3 – Early Trials carboplatin Sensitive : C3	carboplatin Sensitive: C3 – Early Trials carboplatin Sensitive : C3
CDCA3 overexpression	Non Small Cell Lung Cancer	CDCA3 overexpression	Non Small Cell Lung Cancer	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3
EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	osimertinib Resistant: D – Preclinical osimertinib Resistant : D	osimertinib Resistant: D – Preclinical osimertinib Resistant : D
EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	erlotinib Resistant: D – Preclinical erlotinib Resistant : D	erlotinib Resistant: D – Preclinical erlotinib Resistant : D

Associations(4)